Replies to post #4761 on Revance Therapeutics Inc (RVNC)

[stocksrising]

Freakin’ Drunken sailors!!! Still plsses me off!!

Revised 2023 GAAP and Non-GAAP operating expense guidance to reflect the company's exit of the
OPUL® payments business:
• GAAP operating expenses updated from $460 million - $480 million to
$545 million - $585 million